Precision therapy in congenital long QT syndrome

Raquel Neves; Sahej Bains; J. Martijn Bos; Ciorsti MacIntyre; John R. Giudicessi; Michael J. Ackerman

doi:10.1016/j.tcm.2022.06.006

Precision therapy in congenital long QT syndrome

Raquel Neves, Sahej Bains, J. Martijn Bos, Ciorsti MacIntyre, John R. Giudicessi, Michael J. Ackerman

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.

Original language	English (US)
Pages (from-to)	39-47
Number of pages	9
Journal	Trends in cardiovascular medicine
Volume	34
Issue number	1
DOIs	https://doi.org/10.1016/j.tcm.2022.06.006
State	Published - Jan 2024

Keywords

Genetic testing
Long QT syndrome
Precision therapy
Sudden cardiac death

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.tcm.2022.06.006

Cite this

@article{0261ae0862a6420190fcc5d434c2d603,

title = "Precision therapy in congenital long QT syndrome",

abstract = "Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.",

keywords = "Genetic testing, Long QT syndrome, Precision therapy, Sudden cardiac death",

author = "Raquel Neves and Sahej Bains and Bos, {J. Martijn} and Ciorsti MacIntyre and Giudicessi, {John R.} and Ackerman, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2024",

month = jan,

doi = "10.1016/j.tcm.2022.06.006",

language = "English (US)",

volume = "34",

pages = "39--47",

journal = "Trends in cardiovascular medicine",

issn = "1050-1738",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Precision therapy in congenital long QT syndrome

AU - Neves, Raquel

AU - Bains, Sahej

AU - Bos, J. Martijn

AU - MacIntyre, Ciorsti

AU - Giudicessi, John R.

AU - Ackerman, Michael J.

PY - 2024/1

Y1 - 2024/1

N2 - Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.

AB - Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.

KW - Genetic testing

KW - Long QT syndrome

KW - Precision therapy

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=85133787524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133787524&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2022.06.006

DO - 10.1016/j.tcm.2022.06.006

M3 - Review article

C2 - 35772688

AN - SCOPUS:85133787524

SN - 1050-1738

VL - 34

SP - 39

EP - 47

JO - Trends in cardiovascular medicine

JF - Trends in cardiovascular medicine

IS - 1

ER -

Precision therapy in congenital long QT syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this